Biocon, Bangalore-based bio-technology company has got nod from the Drug Controller General of India (DGCI) to promote brease cancer drug Abraxane (Nanoparticles based, albumin bound paclitaxel) in the Indian market.

Abraxane has been sanctioned for handling breast cancer, and would facilitate reasonable access of high-class, helpful care therapy to cancer patients in India.

Abraxane, is a product of Abraxis BioScience, Inc. USA.

Recently, Biocon has also declared a licensing contract with the company for the Abraxane’s commercialization in the Indian market.

In a communiqué to BSE, the company said that Abraxane makes use of albumin, which is a human protein, to deliver paclitaxel unlike the conventional form that uses chemical solvents, like Cremophors which are well-known to give rise to hypersensitive allergenic reactions. This annihilates the need for pre-medication with steroids or antihistamines. This also cuts infusion time from 3 hours for Cremophor based paclitaxel to just 30 minutes for ABRAXANE.